INDEMNIFICATION AGREEMENTIndemnification Agreement • September 18th, 2018 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ], 2018 between Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
Entasis Therapeutics Holdings Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 27th, 2021 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
ENTASIS THERAPEUTICS HOLDINGS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • October 2nd, 2019 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
ENTASIS THERAPEUTICS HOLDINGS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • October 2nd, 2019 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
] Shares Entasis Therapeutics Holdings Inc. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • September 18th, 2018 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 21st, 2019 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Illinois
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2019 by and between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 21st, 2019 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 21, 2019, by and between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
ENTASIS THERAPEUTICS HOLDINGS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFSecurities Warrant Agreement • October 2nd, 2019 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 3rd, 2021 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 3, 2021, by and between Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and Innoviva Strategic Opportunities LLC (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Massachusetts
This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Eric Kimble (“Executive”) and Entasis Therapeutics Inc. (the “Company”) and is effective as of September 6, 2019 (the “Effective Date”).
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN ENTASIS THERAPEUTICS HOLDINGS INC. AND INNOVIVA STRATEGIC OPPORTUNITIES LLC Dated as of May 3, 2021Securities Purchase Agreement • May 3rd, 2021 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of May 3, 2021, is made by and between (i) Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and (ii) Innoviva Strategic Opportunities LLC (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party,” and, collectively as the “Parties.” Capitalized terms used herein and not otherwise defined herein are defined in Article I hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 1st, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 1, 2020 by and among Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated August 27, 2020, by and among the Company and the Investors identified on Exhibit A attached thereto (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 22nd, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
This Investor Rights Agreement (this “Agreement”) is made and entered into as of April 22, 2020 by and between Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and Innoviva, Inc., a Delaware corporation (the “Purchaser”), in connection with that certain Securities Purchase Agreement, dated as of April 12, 2020, by and between the Company and the Purchaser (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
VOTING AGREEMENT by and between Innoviva, Inc. and the stockholder party hereto Dated as of _______, 2020Voting Agreement • April 13th, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
This Voting Agreement (this “Agreement”) is entered into as of [______], 2020, between Innoviva, Inc., a Delaware corporation (“Purchaser”), and the undersigned stockholder (the “Stockholder”).
AGREEMENT AND PLAN OF MERGER by and among ENTASIS THERAPEUTICS HOLDINGS INC., INNOVIVA, INC., and INNOVIVA MERGER SUB, INC. Dated as of May 23, 2022Agreement and Plan of Merger • May 23rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER, dated as of May 23, 2022 (this “Agreement”), by and among Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Parent”), and Innoviva Merger Sub, Inc., a Delaware corporation and wholly owned Subsidiary of Parent (“Merger Sub” and, together with Parent, the “Purchaser Parties”). Capitalized terms used herein (including in the immediately preceding sentence) and not otherwise defined herein shall have the meanings set forth in Section 1.1.
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Entasis Therapeutics LTD • August 17th, 2018 • Pharmaceutical preparations
This Collaboration Agreement relating to the development, manufacture and commercialisation of zoliflodacin is entered into on the 4th day of July 2017 (the “Effective Date”) by and between:
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • June 7th, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Massachusetts
WHEREAS, the Employer is contemplating entering into that certain merger agreement, dated as of the date hereof, pursuant to which, among other things, Innoviva, Inc. and Innoviva Merger Sub, Inc., a wholly owned subsidiary of Innoviva, will commence a tender offer to acquire all of the shares of common stock, par value $0.001 per share, of the Employer, and subsequently consummate a merger under Section 251(h) of the Delaware General Corporations Law of Innoviva Merger Sub, Inc. with and into Employer, with Employer being the surviving corporation (collectively, the “Transactions”);
AMENDMENT #2 TO AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENTTransfer and Subscription Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations
THIS AMENDMENT #2 TO AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENT (this “Amendment”) is made and entered into as of January 30, 2018 by and among ASTRAZENECA AB (PUBL), a company incorporated in Sweden under no. 556011-7482 (the “Sweden Seller”), ASTRAZENECA UK LIMITED, a company incorporated in England under no. 3674842 (the “UK Seller”), ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (the “US Seller”, and together with the Sweden Seller and the UK Seller, the “AZ Entities”), ENTASIS THERAPEUTICS LIMITED, a private limited company incorporated in England and Wales (the “UK Company”), and ENTASIS THERAPEUTICS INC., a Delaware corporation and a wholly owned subsidiary of the UK Company (the “US Company”, and together with the UK Company, the “Companies”). Capitalized terms not herein defined shall have the meanings ascribed to them in the Agreement (as defined below).
ENTASIS THERAPEUTICS HOLDINGS INC. STOCK INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (SENIOR MANAGEMENT)Incentive Stock Option Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations • Delaware
THIS OPTION (the “Option”) is hereby granted as of [ ] (the “Date of Grant”) by Entasis Therapeutics Holdings Inc. (the “Company”) to [ ] (the “Optionee”) pursuant to the Entasis Therapeutics Holdings Inc. Amended and Restated Stock Incentive Plan (the “Plan”) and is subject to the terms and conditions set forth therein and as set out in this agreement (“Award Agreement”). Capitalized terms used herein shall, unless otherwise required by the context, have the meaning ascribed to such terms in the Plan.
AMENDMENT NO. 1 TO THE INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 23rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
This AMENDMENT NO. 1 TO THE INVESTOR RIGHTS AGREEMENT (this “Amendment”) is entered into as of May 23, 2022, by and between Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”) and Innoviva, Inc., a Delaware corporation (the “Purchaser”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the IRA (as defined below).
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations • Delaware
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of April 25, 2018 (the “Effective Date”), by and between ENTASIS THERAPEUTICS HOLDINGS INC., a Delaware corporation, having a place of business at 35 Gatehouse Drive, Waltham, MA 02451, United States of America (“Entasis”), and Zai Lab (Shanghai) Co., Ltd., a limited company organized under the laws of the PRC, having a place of business at 4560 Jinke Rd, Bldg. 1, 4/F, Pudong, Shanghai, China, 201210 (“Zai”). Entasis and Zai are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENTTransfer and Subscription Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations
THIS AMENDMENT TO AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENT (this “Amendment”) is made and entered into as of August 28, 2017 by and among ASTRAZENECA AB (PUBL), a company incorporated in Sweden under no. 556011-7482 (the “Sweden Seller”), ASTRAZENECA UK LIMITED, a company incorporated in England under no. 3674842 (the “UK Seller”), ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (the “US Seller”, and together with the Sweden Seller and the UK Seller, the “AZ Entities”), ENTASIS THERAPEUTICS LIMITED, a private limited company incorporated in England and Wales (the “UK Company”), and ENTASIS THERAPEUTICS INC., a Delaware corporation and a wholly owned subsidiary of the UK Company (the “US Company”, and together with the UK Company, the “Companies”). Capitalized terms not herein defined shall have the meanings ascribed to them in the Agreement (as defined below).
ENTASIS THERAPEUTICS HOLDINGS INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 18th, 2018 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 14th day of September, 2018, by and among Entasis Therapeutics Holdings Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and the investors listed on Schedule A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANTEntasis Therapeutics Holdings Inc. • September 1st, 2020 • Pharmaceutical preparations • New York
Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that [●], or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York City time) on [●], [2025]4 shares of Common Stock, $0.001 par value per share, of the Company (“Common Stock”), at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively. This Warrant is one of the Warrants (the “Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated as of [●], 20205, by and among the Company and each of the investors party thereto (the “Pu
Entasis Therapeutics Holdings Inc. Restricted Stock Unit Grant AgreementRestricted Stock Unit Award Agreement • November 6th, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
Pursuant to the Restricted Stock Unit Grant notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Entasis Therapeutics Holdings Inc. (the “Company”) has awarded you (“Participant”) a Restricted Stock Unit Award (the “Award”) pursuant to the Company’s 2018 Equity Incentive Plan (the “Plan”) to be issued the number of Restricted Stock Units/shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or the Grant Notice shall have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows:
ENTASIS THERAPEUTICS HOLDINGS INC. STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENTNonqualified Stock Option Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations • Delaware
THIS OPTION (the “Option”) is hereby granted as of [ ] (the “Date of Grant”) by Entasis Therapeutics Holdings Inc. (the “Company”) to [ ] (the “Optionee”) pursuant to the Entasis Therapeutics Holdings Inc. Amended and Restated Stock Incentive Plan (the “Plan”) and is subject to the terms and conditions set forth therein and as set out in this agreement (“Award Agreement”). Capitalized terms used herein shall, unless otherwise required by the context, have the meaning ascribed to such terms in the Plan.
Amendment to Incentive Stock Option Agreement (Employees) Issued under Amended and Restated Stock Incentive PlanIncentive Stock Option Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment to Nonqualified Stock Option Agreement (Employees) (“Amendment”) issued under the Amended and Restated Stock Incentive Plan (the “Plan”) of Entasis Therapeutics Holdings Inc. (the “Company”) is made effective as of November 10, 2021 (“Effective Date”) and modifies the outstanding Incentive Stock Options Agreement(s) (Senior Management) (“Option Agreements”) existing as of the Effective Date between the Company and Optionee. Capitalized terms not explicitly defined in this Amendment or the Option Agreement(s), shall have the meanings set forth in the Plan.
AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENTAssignment and Assumption Agreement • August 17th, 2018 • Entasis Therapeutics LTD • Pharmaceutical preparations
This AMENDED AND RESTATED BUSINESS TRANSFER AND SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of March , 2016, is entered into by and among ASTRAZENECA AB (PUBL), a company incorporated in Sweden under no. 556011-7482 (the “Sweden Seller”), ASTRAZENECA UK LIMITED, a company incorporated in England under no. 3674842 (the “UK Seller”), ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (the “US Seller”, and together with the Sweden Seller and the UK Seller, the “Sellers”), ENTASIS THERAPEUTICS LIMITED, a private limited company incorporated in England and Wales (the “UK Company”), and ENTASIS THERAPEUTICS INC., a Delaware corporation and a wholly owned subsidiary of the UK Company (the “US Company”, and together with the UK Company, the “Companies”).
Amendment to Nonqualified Stock Option Agreement (Senior Management) Issued under Amended and Restated Stock Incentive PlanNonqualified Stock Option Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment to Nonqualified Stock Option Agreement (Senior Management) (“Amendment”) issued under the Amended and Restated Stock Incentive Plan (the “Plan”) of Entasis Therapeutics Holdings Inc. (the “Company”) is made effective as of November 10, 2021 (“Effective Date”) and modifies the outstanding Non-Qualified Stock Options Agreement(s) (Senior Management) (“Option Agreements”) existing as of the Effective Date between the Company and Optionee. Capitalized terms not explicitly defined in this Amendment or the Option Agreement(s), shall have the meanings set forth in the Plan.
DNDi Drugs for Neglected Diseases initiativeEntasis Therapeutics Holdings Inc. • March 29th, 2019 • Pharmaceutical preparations
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 1st, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 27, 2020 by and among Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
ENTASIS THERAPEUTICS HOLDINGS INC. RESTRICTED STOCK UNIT GRANT AGREEMENT (EMPLOYEE/D & O)Restricted Stock Unit Award Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
Pursuant to the Restricted Stock Unit Grant notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Entasis Therapeutics Holdings Inc. (the “Company”) has awarded you (“Participant”) a Restricted Stock Unit Award (the “Award”) pursuant to the Company’s 2018 Equity Incentive Plan (the “Plan”) to be issued the number of Restricted Stock Units/shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or the Grant Notice shall have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows:
Amendment to Option Agreement Issued under 2018 Equity Incentive PlanOption Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment to Option Agreement (“Amendment”) issued under the 2018 Equity Incentive Plan (the “Plan”) of Entasis Therapeutics Holdings Inc.’s (the “Company”) is made effective as of November 10, 2021 (“Effective Date”) and modifies the Option Agreement(s) existing as of the Effective Date between the Company and Optionholder. Capitalized terms not explicitly defined in this Amendment or the Option Agreement, shall the meaning set forth in the Plan.
OPTION AGREEMENT (AMENDED) (EMPLOYEES/D & Os) (2018 EQUITY INCENTIVE PLAN) (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Option Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement (Amended), Entasis Therapeutics Holdings Inc. (the “Company”) has granted you an option under its 2018 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.
Amendment to Restricted Stock Unit Grant Agreement Issued under 2018 Equity Incentive PlanRestricted Stock Unit Grant Agreement • March 3rd, 2022 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment to Restricted Stock Unit Grant Agreement (“Amendment”) issued under the 2018 Equity Incentive Plan (the “Plan”) of Entasis Therapeutics Holdings Inc. (the “Company”) is made effective as of November 10, 2021 (“Effective Date”) and modifies the outstanding Restricted Stock Unit Agreement(s) (“RSU Agreements”) existing as of the Effective Date between the Company and Participant. Capitalized terms not explicitly defined in this Amendment or the Option Agreement, shall have the meanings set forth in the Plan.
